Passage Bio PASG Stock
Passage Bio Price Chart
Passage Bio PASG Financial and Trading Overview
| Passage Bio stock price | 1.19 USD |
| Previous Close | 0.91 USD |
| Open | 0.94 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 1300 |
| Day's Range | 0.91 - 0.95 USD |
| 52 Week Range | 0.9 - 2.84 USD |
| Volume | 208.32K USD |
| Avg. Volume | 204.81K USD |
| Market Cap | 51.79M USD |
| Beta (5Y Monthly) | 0.995684 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.86 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.29 USD |
PASG Valuation Measures
| Enterprise Value | -91106024 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.60769236 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.30404106 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.837 |
Trading Information
Passage Bio Stock Price History
| Beta (5Y Monthly) | 0.995684 |
| 52-Week Change | -56.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.84 USD |
| 52 Week Low | 0.9 USD |
| 50-Day Moving Average | 1.01 USD |
| 200-Day Moving Average | 1.27 USD |
PASG Share Statistics
| Avg. Volume (3 month) | 204.81K USD |
| Avg. Daily Volume (10-Days) | 552.19K USD |
| Shares Outstanding | 54.63M |
| Float | 28.65M |
| Short Ratio | 2.88 |
| % Held by Insiders | 8.96% |
| % Held by Institutions | 66.34% |
| Shares Short | 268.63K |
| Short % of Float | 0.61% |
| Short % of Shares Outstanding | 0.48% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.74% |
| Return on Equity (ttm) | -56.52% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -108791000 USD |
| Net Income Avi to Common (ttm) | -127652000 USD |
| Diluted EPS (ttm) | -2.09 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 167.77M USD |
| Total Cash Per Share (mrq) | 3.07 USD |
| Total Debt (mrq) | 26.95M USD |
| Total Debt/Equity (mrq) | 15.82 USD |
| Current Ratio (mrq) | 9.953 |
| Book Value Per Share (mrq) | 3.118 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -95945000 USD |
| Levered Free Cash Flow (ttm) | -52611124 USD |
Profile of Passage Bio
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | One Commerce Square |
| ZIP | 19103 |
| Phone | 267 866 0311 |
| Website | https://www.passagebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 85 |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Passage Bio Stock
What is a current PASG stock price?
Passage Bio PASG stock price today per share is 1.19 USD.
How to purchase Passage Bio stock?
You can buy PASG shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Passage Bio?
The stock symbol or ticker of Passage Bio is PASG.
Which industry does the Passage Bio company belong to?
The Passage Bio industry is Biotechnology.
How many shares does Passage Bio have in circulation?
The max supply of Passage Bio shares is 69.38M.
What is Passage Bio Price to Earnings Ratio (PE Ratio)?
Passage Bio PE Ratio is now.
What was Passage Bio earnings per share over the trailing 12 months (TTM)?
Passage Bio EPS is -1.86 USD over the trailing 12 months.
Which sector does the Passage Bio company belong to?
The Passage Bio sector is Healthcare.
Passage Bio PASG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}